Ipsen is an innovation-driven global specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on its activities in specialty medicine, growth drivers in targeted therapeutic areas (oncology, endocrinology, neurology and haematology), combined with primary care products which contribute significantly to its research financing. Consolidated sales amounted to €971 million in 2008 while total revenue exceeded €1 billion. 

• Ipsen has production sites in France, United Kingdom, Ireland and China where more than 1,100 employees are dedicated to the manufacturing and supply our products,
• The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2008, Research and Development expenditure was approximately €183 million, close to 19% of consolidated sales.

  Established in Dublin in 1989, Ipsen Manufacturing Ireland Ltd is a specialised Peptide bulk Active Pharmaceutical Ingredient facility employing over 80 people, with over 80% of employees having a 3rd Level Education. The plant supplies the active ingredient for two of the group’s major products.

  Ipsen strives to deliver significant improvements in patients’ health and quality of life by providing effective therapeutic solutions to fulfil unmet medical needs. By being part of an innovation driven international specialty pharmaceutical group, whether you are part of Research & Development or another Business area, you are helping to make a difference.

  Please visit our Website (www.ipsen.com) which provides interesting information on the Ipsen Group, products and updated news.